APRES

18 Aug, 10

Listen

Stop

APRES

Study Patients

159 patients either 1-2 days post PTCA or 5-7 days post CABG

Study Treatment

Ramipril 10 mg/day vs Other ACE inhibitors

Study Period

2.5 years

Results

Ramipril significantly reduced the risk of composite endpoint of cardiac death, acute MI or clinical HF by 58%
Composite endpoint of cardiac death or MI was reduced significantly by 78% while the composite of cardiac death or HF was reduced by 61%
The risk of cardiac death was reduced by 86% with ramipril

Conclusion

Reduction in composite outcome indicates the benefits with ramipril post revascularization

J Am Coll Cardiol 2000;35:881-8

Related Topics